The Patent Trial and Appeal Board said that challenged claims of Aerin Medical Inc.'s patent that discloses methods and devices for treating nasal airways are unpatentable as obvious over prior art, in an inter partes review by Neurent Medical Inc. & Neurent Medical Ltd. The board said that the challenged claims are obvious over various combinations of prior art, including prior art that discloses methods and apparatus for ablating at least a portion of a nasal concha to reduce its size and improve air flow through the nasal meatus, that describes an endometrial ablation device that passes RF energy to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.